Drugs / Autologous CD22 CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04088864 | Jan 2020 → Nov 2021 | childhood acute lymphoblastic leukemia | Kara Lynn Davis | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD22 CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04088864 ↗ |
| Action | Deplete | “cancer killing ability of a cell therapy against a new cancer target (CD22)” NCT04088864 ↗ |
| Modality | Cell therapy | “Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)” NCT04088864 ↗ |
| Route | Intravenous | “Autologous CD22 CAR T cells will be administered intravenously” NCT04088864 ↗ |
| Target | CD22 | “new cancer target (CD22)” NCT04088864 ↗ |